Placebo (N=32)

5mg CCX140-B (N=63)

10mg CCX140-B (N=32)

30mgPioglitazone (N=32)

All (N=159)

Mean ± SD age—yr

58.5 ± 8.02

58.8 ± 6.36

57.5 ± 5.51

60.0 ± 6.36

58.7 ± 6.56

Male—no. (%)

20 (62.5)

40 (63.5)

21 (65.6)

20 (62.5)

101 (63.5)

Race—no. (%)
Caucasian
Asian
Black/African
Other


32 (100.0)
0
0
0


62 (98.4)
1 (1.6)
0
0


30 (93.8)
1 (3.1)
0
1 (3.1)


31 (96.9)
0
1 (3.1)
0


155 (97.5)
2 (1.3)
1 (0.6)
1 (0.6)

Mean ± SD body mass index—kg/m2)

32.4 ± 4.04

32.3 ± 4.58

32.1 ± 4.30

31.3 ± 4.68

32.1 ± 4.42

Mean ± SD waist circumference—cm

107.8 ± 11.56

107.7 ± 12.59

106.7 ± 13.21

105.3 ± 10.83

107.1 ± 12.12

Mean ± SD diabetes duration—months

81.0 ± 60.41

83.7 ± 66.43

75.3 ± 57.91

89.4 ± 52.62

82.6 ± 60.58

MCP-1 base pair at -2518 position = GG or AG—no. (%)

14 (43.8%)

30 (47.6%)

15 (46.9%)

15 (46.9%)

74 (46.5%)

Mean ± SD FPG—mg/dL

182.9 ± 52.95

166.0 ± 34.23

163.1 ± 37.08

169.8 ± 40.40

169.6 ± 40.61

Mean ± SD fasting insulin—mIU/L

18.0 ± 11.86

16.6 ± 16.18

17.9 ± 17.48

13.5 ± 8.27

16.5 ± 14.38

Mean ± SD total adiponectin—mg/mL

6.4 ± 3.67

6.2 ± 3.34

6.4 ± 2.73

6.2 ± 3.58

6.2 ± 3.32

Mean ± SD HOMA-IR

8.5 ± 6.62

7.2 ± 8.64

7.3 ± 7.00

5.7 ± 3.49

7.2 ± 7.14

Mean ± SD HbA1c— %

7.6 ± 1.00

7.4 ± 0.74

7.3 ± 0.81

7.6 ± 0.86

7.5 ± 0.83

Mean ± SD fructosamine— μmol/L

291.6 ± 51.60

285.3 ± 36.48

286.3 ± 43.47

289.6 ± 36.05

287.6 ± 40.87

Mean ± SD plasma MCP-1—pg/mL

444.9 ± 129.72

432.0 ± 138.35

383.8 ± 78.19

420.7 ± 81.13

423.0 ± 117.87

Mean ± SD C-reactive protein— mg/L

4.3 ± 6.00

6.3 ± 11.63

3.2 ± 2.91

6.9 ± 9.58

5.4 ± 9.11

Table 1: Demographics and baseline characteristics of the study population.